Open AccessPractical consensus recommendations on management of triple-negative metastatic breast cancer
Author(s) -
R Rangarao,
B K Smruti,
Kiranjeet Singh,
Ayush Gupta,
Sandeep Batra,
Raghuveer Choudhary,
Sonali Sahani,
Vedant Kabra,
Purvish M. Parikh,
Sandeep Aggarwal
Publication year - 2018
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/sajc.sajc_118_18
Subject(s) - medicine , triple negative breast cancer , metastatic breast cancer , oncology , breast cancer , chemotherapy , expert opinion , cancer , disease , estrogen receptor , intensive care medicine
Patients with breast cancer along with metastatic estrogen and progesterone receptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negative tumors are referred to as having metastatic triple-negative breast cancer (mTNBC) disease. Resistance to current standard therapies such as anthracyclines or taxanes limits the available options for previously treated patients with metastatic TNBC to a small number of non-cross-resistant regimens, and there is currently no preferred standard chemotherapy. Clinical experience suggests that many women with triple-negative metastatic breast cancer (MBC) relapse quickly. Expert oncologist discussed about new chemotherapeutic strategies and agents used in treatment of mTNBC and the expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.